Menu
Search

News

Swiss Deep Tech News & Analysis

Stay informed on the Swiss technology landscape. This is your central resource for Deep Tech News, combining key developments from across the ecosystem with original, data-driven analysis from the Deep Tech Nation Foundation. We track and report on significant technological milestones, funding rounds, and research to provide a comprehensive overview for international investors, partners, and researchers.

Curated Newsfeed

See all news

DTN Highlights

See DTN Highlights

  • Indivi attracts Infosys Innovation Fund as strategic investor

    Together with Infosys, Indivi aims to fundamentally unlock early-stage clinical development elevating tech-science at the epicenter of precision drug development in neurology. With its platform…

    startupticker.ch

    • Indivi's smartphone platform enables frequent assessment of motor and cognitive function to detect early treatment effects in neuroscience trials.
    • Infosys' investment helps Indivi scale its commercial organization and expand its digital biomarker platform across neuroscience programs.
    • Infosys and Indivi combine AI and machine learning with neuroscience expertise to accelerate drug development for Parkinson's and Alzheimer's.
    startupticker.ch: Indivi attracts Infosys Innovation Fund as strategic investor

  • Bruker makes minority investment in Atinary

    Bruker Corporation entered into an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs technologies and AI-driven R&D with applications in pharmaceuticals,…

    startupticker.ch

    • Bruker invested in Atinary to integrate analytical instruments, lab automation, and AI into Self-Driving Labs platforms.
    • Atinary's SDLabs platform automates Design-Make-Test-Analyze-Learn workflows using AI agents for faster discovery.
    • Demo labs in Basel and Boston integrate Chemspeed robotics, Bruker NMR, and Atinary's agentic AI technology.
    startupticker.ch: Bruker makes minority investment in Atinary

  • Boehringer Ingelheim acquires equine health startup Evax

    Boehringer Ingelheim has acquired Evax AG, a Swiss biotech company focused on therapeutic vaccines to address significant unmet needs in horses, particularly for the treatment of allergic…

    startupticker.ch

    • Boehringer Ingelheim acquired Swiss biotech Evax AG, which develops therapeutic vaccines using virus-like particles for allergic skin diseases in horses.
    • Evax's vaccine targets the root cause of equine allergies, offering longer-lasting relief than current shampoo and corticosteroid treatments.
    • The acquisition expands Boehringer Ingelheim's therapeutic vaccine portfolio for animal health, following its 2024 Saiba Animal Health acquisition.
    startupticker.ch: Boehringer Ingelheim acquires equine health startup Evax

  • London-based market intelligence company acquires Square Commodities

    FGE NexantECA has completed the acquisition of Morges-based Square Commodities ("SquareCo"), the leading research and data analytics platform specialising in the global renewable fuels market. Founded…

    startupticker.ch

    • FGE NexantECA acquired Square Commodities, a renewable fuels research platform, to enhance oil demand modeling with regulatory expertise.
    • Square Commodities will integrate into Lumen, FGE NexantECA's AI platform, to improve renewable fuels market analysis capabilities.
    • Founder Olivier Pellegrinelli will lead renewable fuels research, bringing over a decade of biofuels regulation and market experience.
    startupticker.ch: London-based market intelligence company acquires Square Commodities

  • Vaderis Therapeutics closes USD 152 million Series B Financing

    Basel-based Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, today announced the closing of a private $152 million…

    startupticker.ch

    • Vaderis raised $152M in Series B funding to advance engasertib into Phase 3 trials for hereditary hemorrhagic telangiectasia (HHT).
    • Engasertib, an oral AKT inhibitor, showed sustained improvements in HHT patients and could be the first approved HHT-specific therapy.
    • The HEROIC Phase 3 study is a global, randomized, placebo-controlled trial for moderate-to-severe HHT across three continents.
    startupticker.ch: Vaderis Therapeutics closes USD 152 million Series B Financing

  • Terra Quantum partners with Apex.AI on quantum-safe security

    Swiss startup Terra Quantum and California-based Apex.AI have demonstrated a quantum-safe security solution for long-lived, cloud-connected software-defined systems. The joint solution is designed to help…

    startupticker.ch

    • Terra Quantum and Apex.AI demonstrated a quantum-safe security solution using NIST-standardized post-quantum cryptography.
    • The solution maintains compatibility with existing software while preparing organizations for future quantum computing threats.
    • Mission-critical aerospace, defense, and infrastructure systems need post-quantum security now as today's devices will outlast current standards.
    startupticker.ch: Terra Quantum partners with Apex.AI on quantum-safe security

  • Exclaim Robotics raises USD 4.95 million for data centre repair robots

    Exclaim Robotics has emerged from stealth with a USD 4.95 million pre-seed round co-led by Founderful and Playfair. The Zurich-based startup is building autonomous mobile…

    startupticker.ch

    • Exclaim Robotics raised $4.95M to build autonomous robots for hazardous maintenance tasks in AI data centres, addressing 800V DC power system safety risks.
    startupticker.ch: Exclaim Robotics raises USD 4.95 million for data centre repair robots

  • Two Swiss biotechs clear US regulatory steps for heart and nerve therapies

    HAYA Therapeutics has won Fast Track designation from the US Food and Drug Administration for its lead cardiac fibrosis candidate, while Oculis has received FDA…

    startupticker.ch

    • HAYA Therapeutics received FDA Fast Track designation for HTX-001, an antisense oligonucleotide for cardiac fibrosis in hypertrophic cardiomyopathy.
    • Oculis can cross-reference existing data to expand Privosegtor into acute multiple sclerosis relapse treatment, per FDA feedback.
    • Privosegtor showed positive Phase 2 data in optic neuritis and uses the same 3mg/kg dose across MS relapse types.
    startupticker.ch: Two Swiss biotechs clear US regulatory steps for heart and nerve therapies

  • AB2 Bio receives USD 30 million from Nippon Shinyaku

    Lausanne-based AB2 Bio has received a USD 30 million payment after Japanese pharmaceutical company Nippon Shinyaku exercised its option to commercialise Tadekinig alfa in the…

    startupticker.ch

    • AB2 Bio received $30M from Nippon Shinyaku exercising its Tadekinig alfa US commercialization option, with up to $600M in milestone and royalty payments.
    • Tadekinig alfa, a recombinant IL-18 binding protein, treats rare monogenic hyperinflammatory syndrome by neutralizing excess IL-18.
    • The drug has FDA breakthrough therapy and rare pediatric disease designations, making it eligible for a priority review voucher.
    startupticker.ch: AB2 Bio receives USD 30 million from Nippon Shinyaku

  • Ahead Health raises USD 10 million and opens first markets outside Switzerland

    Zurich-based Ahead Health has raised USD 10 million in a round led by Vienna-based 3VC and existing investor RTP Global, and is using the capital…

    startupticker.ch

    • Ahead Health raised $10M led by 3VC and RTP Global to expand its AI preventive healthcare platform from Switzerland into Germany and the Netherlands.
    • The platform combines full-body MRI, 80+ biomarker blood tests, and AI analysis to detect silent cardiovascular and metabolic diseases early.
    • Ahead Health partners with 20+ clinics and labs, using repeat testing against individual baselines for personalized disease prevention.
    startupticker.ch: Ahead Health raises USD 10 million and opens first markets outside Switzerland

  • Quantonation leads USD 25.5 million seed round for ETH spin-off ZuriQ

    ZuriQ has raised USD 25.5 million in a seed round to scale the trapped-ion quantum processors it is building on a two-dimensional chip architecture. The…

    startupticker.ch

    • ZuriQ raised $25.5M for trapped-ion quantum processors using a novel 2D chip architecture eliminating junction bottlenecks.
    • ZuriQ demonstrated a 3×3 array of nine controlled ions, the largest 2D trapped-ion array, using standard manufacturing.
    • ZuriQ's static magnetic field design enables ions to move freely in any direction, overcoming 1D architecture limitations.
    startupticker.ch: Quantonation leads USD 25.5 million seed round for ETH spin-off ZuriQ

  • Neurimmune closes licensing deal of up to USD425 million

    Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125…

    startupticker.ch

    • Neurimmune sold cliramitug royalty interest to Royalty Pharma for up to $425M, with $125M upfront.
    • Non-dilutive funding supports Neurimmune's R&D while Alexion/AstraZeneca develops cliramitug for ATTR-CM.
    • Royalty Pharma receives 3-4% royalties on cliramitug sales plus milestone payments.
    startupticker.ch: Neurimmune closes licensing deal of up to USD425 million